Contineum Therapeutics News and Activities
Presence
Headquarters: United States (USA)
Contineum Therapeutics is a company listed under the stock ticker CTNM (US).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Contineum Therapeutics
- Carmine Stengone, Director, President and Chief Executive Officer
- Evert Schimmelpennink, Director
- Olivia Ware, Director
Popular executive movements at Contineum Therapeutics
- Brian Wiens has joined the company as Vice President, Head of Biometrics (posted on May 19 2026).
- James Swaney has joined the company as Vice President, Translational Sciences (posted on March 30 2026).
Create your alert
to follow the executive moves at Contineum Therapeutics.
Biotechnology
Contineum Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Contineum Therapeutics
- Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 | Contineum Therapeutics
- Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference | Contineum Therapeutics
- Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain | Contineum Therapeutics
- Contineum Therapeutics to Attend Upcoming Investor Conferences | Contineum Therapeutics
- News Releases | Contineum Therapeutics
- News Releases | Contineum Therapeutics
- Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Contineum Therapeutics
- Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences | Contineum Therapeutics
- Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Contineum Therapeutics
- Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis | Contineum Therapeu
- View more press releases Close
Social media about Contineum Therapeutics
- Contineum Therapeutics on Wikipedia, Google News & Yahoo Finance
- Contineum Therapeutics on LinkedIn, X (Twitter) & YouTube
